Name (Synonyms) | Correlation | |
---|---|---|
D004211 | Disseminated Intravascular Coagulation NIH | 0.50 |
D014808 | Vitamin D Deficiency NIH | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0005521 | Disseminated intravascular coagulation HPO | 0.50 |
HP:0100512 | Low levels of vitamin D HPO | 0.38 |
There is one clinical trial.
Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Untreated CAC leads to microangiopathic thromboses, causing multiple systems organ failure and consuming enormous healthcare resources. Identifying strategies to prevent CAC are therefore crucial to reducing COVID-19 hospitalization rates. The pathogenesis of CAC is unknown, but there are major overlaps between severe COVID-19 and vitamin D insufficiency (VDI). We hypothesize that VDI is a major underlying contributor to CAC. Preliminary data from severe COVID-19 patients in New Orleans support this hypothesis. The purpose of the proposed multi-center, prospective, randomized controlled trial is to test the hypothesis that low-risk, early treatment with aspirin and vitamin D in COVID-19 can mitigate the prothrombotic state and reduce hospitalization rates.
Description: Hospitalization for COVID-19 symptoms
Measure: Hospitalization Time: 2 weeks